News | Coronavirus (COVID-19) | September 03, 2020

Possible Blood Clotting Mechanism in COVID-19 Found

Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology

Examples of pulmonary embolism clots caused by COVID-19 seen on a chest CT. From the journal Radiology


September 3, 2020 — Why so many COVID-19 (SARS-CoV-2) patients get blood clots (thrombosis) remains uncertain. But scientists at Uppsala University and the University Hospital have now identified a mechanism they believe to be implicated. A particular protein triggers a part of our immune system that can boost the blood's tendency to coagulate and form clots. The study is now published in Thrombosis and Haemostasis.[1]

Since thrombosis has proved to be a common complication in severe COVID-19, most people receiving hospital care for the disease get them.

In a new study, researchers at Uppsala University have found that a key mechanism of clot formation in COVID-19 may be activation of what is known as the complement system, which is part of the immune system we are born with. This can be initiated by certain proteins, one example being mannose-binding lectin (MBL).

Sixty-five patients receiving intensive care at Uppsala University Hospital had their MBL levels and activity measured. In all those who developed thrombosis during their hospital stay, MBL activity and levels were found to be elevated.

The scientists believe that when the complement system is activated by means of MBL, it contributes to a massive activation of the blood coagulation system as well. This change, seen in many COVID-19 patients, results in thrombosis. The study indicates that the complement system not only is included in our immune defenses, but can also serve to boost the blood's clotting propensity.

"Our results are especially interesting since we think MBL activates blood coagulation in a way that blood-thinning drugs can't prevent. This might explain why so many patients suffer from clots in spite of treatment," says the study's lead author Oskar Eriksson, a doctor at the University Hospital and researcher at the Department of Immunology, Genetics and Pathology, Uppsala University.

The scientists think their results might eventually lead to testing of MBL activity in COVID-19 patients to identify those who are at high risk of getting thrombosis. MBL could also be a possible target in future development of drugs to prevent the condition.

Facts About the Complement System

Part of our innate immune system, the complement system comprises some 50 proteins that circulate in the blood. It evolved to recognize, and swiftly render harmless, alien substances like bacteria and viruses, or dead and damaged cells, in the bloodstream.

The complement system thus has an important "clean-up" function. But when activation is excessively powerful, for example in severe infections, the system can become overactive and tackle the body's own cells as well, which results in tissue damage.

 

Reference: 

1. Oskar Eriksson, Michael Hultström, Barbro Persson, et al. Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients. Thrombosis and Haemostasis. DOI: 10.1055/s-0040-1715835. 


Related Content

News | Antiplatelet and Anticoagulation Therapies

August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...

Home August 28, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

March 24, 2023 — According to the U.S. Food and Drug Administration (FDA), Ascend Laboratories LLC is voluntarily ...

Home March 24, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
News | Antiplatelet and Anticoagulation Therapies

November 17, 2021 — Taking daily low-dose aspirin for seven years did not affect the risk of dementia or mental decline ...

Home November 17, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

November 9, 2021 — Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE ...

Home November 09, 2021
Home
News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
Subscribe Now